drugset / Trial / NCT03285477

A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp

NCT03285477

Phase 3 Completed 351 enrolled Almirall, S.A. Athenex, Inc. · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This Phase III study is designed to evaluate the efficacy and safety of KX2-391 Ointment in adult participants when applied to an area of skin containing 4-8 stable, clinically typical Actinic Keratosis (AK) lesions on the face or scalp.

Timeline

Start
2017-09-18
Primary completion
2018-05-03
Completion
2019-04-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Tirbanibulin Small molecule 1 % Topical

Indications